Amirali Salmasi
Associate Professor
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Amirali Salmasi is an Associate Professor at UC San Diego Health System in the United States. His research focuses on the role of radical cystectomy, particularly in assessing clinically node-positive bladder cancer. His recent work includes a significant study within the US Veterans Health Administration.
Articles (3)
Introduction We evaluated the incidence of anxiety, depression, and suicidality amongst TC survivors and the impact of chemotherapy on these outcomes. Methods We conducted a retrospective cohort study of men diagnosed with TC in the United States Veterans Affairs Health System from 1990 to 2016. De novo anxiety or depression was a composite endpoint comprised of diagnosis codes for anxiety, depression, or medications used to treat these diagnoses. Incident suicidality was defined as a diagnosis code for suicidal ideation. 2022 TC patients were compared in a 1:3 ratio to 6375 controls. Cox proportional hazards models were employed for statistical analysis. Results Mean age at diagnosis was 42.6 years. 5‐year cumulative incidence of anxiety or depression was 53.4% in TC patients and 35% for controls ( p < 0.001). TC patients were more likely to develop anxiety or depression (HR 1.66, 95% CI 1.56–1.78, p < 0.001) and suicidality (HR 22.99, 95% CI 17.52–30.17, p < 0.001). In the TC cohort, factors associated with a higher risk of anxiety or depression were divorce (HR 1.15, 95% CI 1.00–1.32, p = 0.044), unemployment (HR 1.68, 95% CI 1.47–1.9, p < 0.001), and receipt of chemotherapy (HR 1.20, 95% CI 1.06–1.35, p < 0.001). Conclusions Psychological morbidity due to depression, anxiety, and suicidality is high among TC survivors. In our analysis chemotherapy increases the rates of psychosocial morbidity. Clinicians should be proactive in screening and intervening for these diagnoses in TC survivors to provide early intervention and improve health comes.
Year:
2026
Year:
2024
Background Non‐canonical WNT family (WNT5A pathway) signaling via WNT5A through ROR1 and its partner, ROR2 , or Frizzled2 ( FZD2 ) is linked to processes driving tumorigenesis and therapy resistance. We utilized a large dataset of urothelial carcinoma (UC) tumors to characterize non‐canonical WNT signaling through WNT5A , ROR1 , ROR2 , or FZD2 expression. Methods NextGen Sequencing of DNA (592 genes or WES)/RNA (WTS) was performed for 4125 UC tumors submitted to Caris Life Sciences. High and low expression of WNT5A , ROR1 , ROR2 , and FZD2 was defined as ≥ top and <bottom quartile of transcripts per million (TPM), respectively. Gene expression profiles were analyzed for a transcriptional signature predictive of response to immunotherapy. Mann–Whitney U and X2/Fisher Exact tests were applied where appropriate, with p ‐values adjusted for multiple comparisons ( p < 0.05). Real‐world overall survival (OS) was obtained from insurance claims data. Results WNT5A pathway gene expression varied significantly between primary versus metastatic sites: WNT5A (25.2 vs. 16.8 TPM), FZD2 (3.2 vs. 4.05), ROR1 (1.7 vs. 2.1), and ROR2 (2.4 vs. 2.6) p < 0.05 for all. Comparison of high‐ and low‐expression subgroups revealed variation in the prevalence of TP53 , FGFR3 , and RB1 pathogenic mutations, as well as increasing T cell‐inflamed scores as expression of the target gene increased. High gene expression for ROR2 (HR 1.31, 95% CI 1.15–1.50, p < 0.001) and FZD2 (HR 1.16, 95% CI 1.02–1.32, p = 0.024) was associated with worse OS. Conclusion Distinct genomic and immune landscapes for the four investigated WNT5A pathway components were observed in patients with UC. External validation studies are needed.
Year:
2024
Collaborators (1)
Rana R. McKay
University of California, San Diego
Make your next move.
Prepare your application
Review drafts before you send them.